Small Molecule Drug Discovery Market To See Massive Growth By 2027 : MERCK KGaA, GlaxoSmithKline plc., AstraZeneca, Gilead Sciences, Inc.

The small molecule drug discovery market was valued at US$ 24,976.14 million in 2019 and is projected to reach US$ 50,823.06 Mn by 2027; it is expected to grow at a CAGR of 9.5% from 2020 to 2027.

Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and, cost-effectiveness. The small molecule drug discovery market is expected to witness huge growth due to increasing approval of small molecule drugs, growing demand for R&D from contract organizations, and rising adoption of small molecules in chronic disease treatments. However, high drug development cost is expected to restrain the growth of the market during the forecast period.

Request Sample Pages of this research study at – https://www.theinsightpartners.com/sample/TIPRE00004774/?source=openpr-10425

The Prominent/Emerging Players in the Small Molecule Drug Discovery Market Research include:

Johnson and Johnson Services, Inc.
Teva Pharmaceutical Industries Ltd
Boehringer Ingelheim International GmbH
Allergan Plc.
Pfizer Inc.
Bristol-Myers Squibb Company
MERCK KGaA
GlaxoSmithKline plc.
AstraZeneca
Gilead Sciences, Inc.

Small Molecule Drug Discovery Market – By Therapeutic Area

Oncology
Central Nervous System
Cardiovascular
Respiratory
Orthopedics
Immunology
Rare Diseases
Other Therapeutic Areas

Small Molecule Drug Discovery Market – By Process/Phase

Target Discovery
Target Validation
Lead Generation and Refinement
Preclinical Development

As per the Centres for Disease Control (CDC), 6 in 10 adults suffer from a chronic condition, such as heart disease, diabetes, cancer, kidney disease, lung disease, or stroke in the US, costing US$ 3.5 trillion to the economy in the US annually for the treatment of these chronic diseases. Chronic diseases are the most significant cause of deaths worldwide, and the number is growing every year. For instance, as per the CDC, more than 1.6 million people are diagnosed with cancer every year in the US.

Order a copy of this research study at – https://www.theinsightpartners.com/buy/TIPRE00004774/?source=openpr-10425

ABOUT US:

The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact US:

If you have any queries about this report or would like further information, please contact us:

North America:+1 646 491 9876

Asia-Pacific:+91 20 6727 8686

This release was published on openPR.